Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study.
Mocci G, Tursi A, Maconi G, Cataletti G, Mantia B, Serio M, Scarcelli A, Pagnini C, Graziani MG, Di Paolo MC, Pranzo G, Luppino I, Paese P, Elisei W, Monterubbianesi R, Faggiani R, Ferronato A, Perini B, Savarino E, Onidi FM, Binaghi L, Usai Satta P, Schiavoni E, Napolitano D, Scaldaferri F, Pugliese D, Pica R, Cocco A, Zippi M, Rodino S, Sebkova L, Rocco G, Sacchi C, Zampaletta C, Gaiani F, De Angelis G, Kayali S, Fanigliulo L, Lorenzetti R, Allegretta L, Scorza S, Cuomo A, Donnarumma L, Della Valle N, Sacco R, Forti G, Antonelli E, Bassotti G, Iannelli C, Luzza F, Aragona G, Perazzo P, Lauria A, Piergallini S, Colucci R, Bianco MA, Meucci C, Giorgetti G, Clemente V, Fiorella S, Penna A, De Medici A, Picchio M, Papa A. Mocci G, et al. Among authors: scorza s. Expert Opin Biol Ther. 2023 Mar;23(3):293-304. doi: 10.1080/14712598.2023.2185510. Epub 2023 Mar 2. Expert Opin Biol Ther. 2023. PMID: 36843568
Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers.
Tursi A, Elisei W, Faggiani R, Allegretta L, Valle ND, Forti G, Franceschi M, Ferronato A, Gallina S, Larussa T, Luzza F, Lorenzetti R, Mocci G, Penna A, Rodino' S, Sebkova L, de Medici A, Pranzo G, Ricciardelli C, Grasso G, Scorza S, Zampaletta C, Picchio M. Tursi A, et al. Among authors: scorza s. Medicine (Baltimore). 2018 Aug;97(34):e11897. doi: 10.1097/MD.0000000000011897. Medicine (Baltimore). 2018. PMID: 30142791 Free PMC article.
Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers.
Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Medici A, Forti G, Franceschi M, Ferronato A, Gallina S, Grasso G, Larussa T, Luzza F, Lorenzetti R, Penna A, Rodino' S, Sebkova L, Lauria A, Piergallini S, Pranzo G, Scorza S, Zampaletta C, Picchio M, Elisei W. Tursi A, et al. Among authors: scorza s. Eur J Intern Med. 2019 Aug;66:85-91. doi: 10.1016/j.ejim.2019.06.006. Epub 2019 Jun 14. Eur J Intern Med. 2019. PMID: 31208827
Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study.
Tursi A, Mocci G, Cuomo A, Allegretta L, Aragona G, Colucci R, Della Valle N, Ferronato A, Forti G, Gaiani F, Graziani MG, Lorenzetti R, Luzza F, Paese P, Penna A, Pica R, Piergallini S, Pranzo G, Rodino S, Scarcelli A, Zampaletta C, Cicerone C, Cocco A, De' Angelis G, Donnarumma L, Franceschi M, Gallina S, Grasso G, Larussa T, Luppino I, Faggiani R, Fanigliulo L, Pagnini C, Perazzo P, Sacco R, Sebkova L, Scorza S, Serio M, De Monti A, Picchio M, Elisei W, Maconi G. Tursi A, et al. Among authors: scorza s. Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):2099-2108. doi: 10.26355/eurrev_202102_25115. Eur Rev Med Pharmacol Sci. 2021. PMID: 33660823 Free article. Clinical Trial.
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
Tursi A, Mocci G, Lorenzetti R, Allegretta L, Brandimarte G, Cassieri C, Colucci R, De Medici A, Faggiani R, Ferronato A, Fiorella S, Forti G, Franceschi M, Gallina S, Giorgetti G, Grasso G, Larussa T, Luzza F, Penna A, Pica R, Piergallini S, Porciello S, Pranzo G, Rodino' S, Scorza S, Sebkova L, Zampaletta C, Elisei W, Picchio M. Tursi A, et al. Among authors: scorza s. Eur J Gastroenterol Hepatol. 2021 May 1;33(5):670-679. doi: 10.1097/MEG.0000000000002087. Eur J Gastroenterol Hepatol. 2021. PMID: 33741797
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Tursi A, Mocci G, Cingolani L, Savarino E, Pica R, Cocco A, Zippi M, Napolitano D, Schiavoni E, Pugliese D, Scaldaferri F, Costa F, Marzo M, Serio M, Scarcelli A, Bolognini L, Bendia E, Maconi G, Cannatelli R, Piergallini S, Bodini G, Calabrese F, Ferronato A, Pranzo G, Elisei W, Monterubbianesi R, Faggiani R, Rodinò S, Sebkova L, Grossi L, Gaiani F, Dè Angelis G, Lorenzetti R, Allegretta L, Cazzato AI, Scorza S, Della Valle N, Sacco R, Forti G, Colucci R, Tonti P, Neve V, Rocco G, Sacchi C, Zampaletta C, Pagnini C, Graziani MG, Di Paolo MC, Onidi FM, Usai Satta P, Picchio M, Papa A. Tursi A, et al. Among authors: scorza s. Expert Opin Pharmacother. 2023 Sep-Dec;24(14):1649-1656. doi: 10.1080/14656566.2023.2230126. Epub 2023 Jun 28. Expert Opin Pharmacother. 2023. PMID: 37358928
Search for Daily Modulation of MeV Dark Matter Signals with DAMIC-M.
Arnquist I, Avalos N, Baxter D, Bertou X, Castelló-Mor N, Chavarria AE, Cuevas-Zepeda J, Dastgheibi-Fard A, De Dominicis C, Deligny O, Duarte-Campderros J, Estrada E, Gadola N, Gaïor R, Hossbach T, Iddir L, Kavanagh BJ, Kilminster B, Lantero-Barreda A, Lawson I, Lee S, Letessier-Selvon A, Loaiza P, Lopez-Virto A, McGuire KJ, Mitra P, Munagavalasa S, Norcini D, Paul S, Piers A, Privitera P, Robmann P, Scorza S, Settimo M, Smida R, Traina M, Vilar R, Warot G, Yajur R, Zopounidis JP; DAMIC-M Collaboration. Arnquist I, et al. Among authors: scorza s. Phys Rev Lett. 2024 Mar 8;132(10):101006. doi: 10.1103/PhysRevLett.132.101006. Phys Rev Lett. 2024. PMID: 38518351
First Measurement of the Nuclear-Recoil Ionization Yield in Silicon at 100 eV.
Albakry MF, Alkhatib I, Alonso D, Amaral DWP, Aralis T, Aramaki T, Arnquist IJ, Ataee Langroudy I, Azadbakht E, Banik S, Bathurst C, Bhattacharyya R, Brink PL, Bunker R, Cabrera B, Calkins R, Cameron RA, Cartaro C, Cerdeño DG, Chang YY, Chaudhuri M, Chen R, Chott N, Cooley J, Coombes H, Corbett J, Cushman P, Das S, De Brienne F, Rios M, Dharani S, di Vacri ML, Diamond MD, Elwan M, Fascione E, Figueroa-Feliciano E, Fink CW, Fouts K, Fritts M, Gerbier G, Germond R, Ghaith M, Golwala SR, Hall J, Harms SAS, Hassan N, Hines BA, Hong Z, Hoppe EW, Hsu L, Huber ME, Iyer V, Kashyap VKS, Kelsey MH, Kubik A, Kurinsky NA, Lee M, Litke M, Liu J, Liu Y, Loer B, Lopez Asamar E, Lukens P, MacFarlane DB, Mahapatra R, Mast N, Mayer AJ, Meyer Zu Theenhausen H, Michaud É, Michielin E, Mirabolfathi N, Mohanty B, Nebolsky B, Nelson J, Neog H, Novati V, Orrell JL, Osborne MD, Oser SM, Page WA, Pandey L, Pandey S, Partridge R, Pedreros DS, Perna L, Podviianiuk R, Ponce F, Poudel S, Pradeep A, Pyle M, Rau W, Reid E, Ren R, Reynolds T, Tanner E, Roberts A, Robinson AE, Saab T, Sadek D, Sadoulet B, Sahoo SP, Saikia I, Sander J, Sattari A, Schmidt B, Schnee RW, Scorza S, Serfass B, Poudel SS, Sincavag… See abstract for full author list ➔ Albakry MF, et al. Among authors: scorza s. Phys Rev Lett. 2023 Sep 1;131(9):091801. doi: 10.1103/PhysRevLett.131.091801. Phys Rev Lett. 2023. PMID: 37721818
26 results